BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation

NEXT STORY
CB2 Insights Launches Health Pulse – A Monthly Medical Report Studying and Assessing Real-World Health Outcomes
PREV STORY
Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma

author_avatar
NASDAQ Market News

Sedor Pharmaceuticals Files NDA for CE-Fosphenytoin for Status Epilepticus

Potential significant advance in treatment of life threatening conditionPAOLI, Pa., May 30, 2018 (GLOBE ...

author_avatar
NASDAQ Market News

RICOVR Healthcare raises $1.5M to commercialize rapid point-of-care testing device for Cannabis & COVID-19

author_avatar
NASDAQ Market News